Zhitong Finance App learned that on May 9, Johnson & Johnson (JNJ.US) Tenojada® (Guseciumab Injection (intravenous infusion)) and Tenoya® (Guseciumab Injection) were approved in China to treat adult patients with moderate to severe active ulcerative colitis who are insufficiently responsive, unresponsive, or intolerant to traditional treatments or biologics.

Zhitongcaijing · 4d ago
Zhitong Finance App learned that on May 9, Johnson & Johnson (JNJ.US) Tenojada® (Guseciumab Injection (intravenous infusion)) and Tenoya® (Guseciumab Injection) were approved in China to treat adult patients with moderate to severe active ulcerative colitis who are insufficiently responsive, unresponsive, or intolerant to traditional treatments or biologics.